SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
疾风少年
Lv3
320 积分
2022-12-01 加入
最近求助
最近应助
互助留言
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
5天前
已完结
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
6天前
已完结
Erratum: Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
7天前
已完结
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
7天前
已关闭
BRCAness revisited
7天前
已完结
An update on PARP inhibitors—moving to the adjuvant setting
9天前
已完结
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
13天前
已完结
Next generation sequencing for diagnosis of severe pneumonia: China, 2010–2018
19天前
已完结
Targeted next generation sequencing is comparable with metagenomic next generation sequencing in adults with pneumonia for pathogenic microorganism detection
20天前
已完结
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
1个月前
已完结
没有进行任何应助
感谢,点赞
6天前
标题有问题【积分已退回】
7天前
无法下载
7天前
点赞,速度真快
1个月前
帮大忙了,么么哒
1个月前
感谢,速度真快
1个月前
感谢,速度真快
3个月前
点赞,速度真快
3个月前
速度真快
3个月前
感谢
5个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论